Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone in advanced solid tumors
NCT02029729Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omaveloxolone in non-small cell lung cancer (NSCLC) and melanoma, sponsored by Biogen. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Dec 2013; status: completed.
02
Drugs
omaveloxolone
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT02029729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029729.